Background: The herbal formula BNO-101 (containing Gentianae
radix, Primulae flos, Rumicis herba, Sambuci flos and
Verbenae herba; ratio 1:3:3:3:3) has been widely employed
as a ‘mucoactive’ agent in Germany for 70 years for the
symptoms of respiratory infections. This paper reviews the
clinical evidence of BNO-101 in sinusitis. Methods: The systematic
search identified 22 studies with BNO-101. Out of
these, 6 controlled trials on sinusitis were reassessed according
to predefined criteria. 4 trials had almost identical
designs and could be examined by meta-analysis. Results:
The database comprised approximately 900 patients, mostly
young adult males. After 2 weeks of treatment, verum was
significantly superior to placebo (2 RCTs, 159 vs. 160 patients,
both add-on to antibacterial treatment). The benefit
regards the patients’ assessment (‘cured’: verum = 61.1%,
placebo = 34.5%), reduction of drain obstruction, headache
and radiological signs (all p < 0.05). Comparing BNO-101 to
ambroxol (2 RCTs, 151 vs. 150 patients, add-on to antibacterials
in 13% of the cases) the patients’ assessment
after 2 weeks showed no difference, although it favoured
BNO-101 in chronic cases (‘cured’ BNO-101 = 37.1%, ambroxol
= 12.5%; p < 0.05). It also favoured BNO-101 concerning
pyorrhoea and headache (p < 0.05). No significant
differences were reported in 2 open randomised trials vs.
N-acetyl-cysteine and vs. the herbal product Myrtol std.
Conclusions: BNO-101, combined with standard antibacterial
therapy, significantly reduces the acute symptoms and
signs of sinusitis. The effects are of the same order of
magnitude as observed with other mucoactive agents. In
the trials investigated BNO-101 had a favourable risk/benefit
ratio, with an incidence of adverse events similar to placebo.